News About: Pharm. Industry
Pharmaceutical industry turnover rate high ... frequent hiring process on board
(The Yakup Shinmoon)
Major pharmaceutical companies are actively posting new employee recruitments for the expected university graduates who are going to graduate on the early next year.
On the end of September,...
Hanmi-Sanofi, First ‘ARB-Statin’ FDC new drug approval
‘Robelito’ appointed reexamination in 6 years, local co-marketing
(The Yakup Shinmoon)
The fixed dose combination (FDC) of hypertension drug Irbesratan and hyperlipidemia drug Atorvastatin get approved to sell in ...
Market based ATP “Market disruption Abolition” VS “Maintain after compleme
Market based Actual Transaction Price(ATP) “Market disruption Abolition” VS “Maintain after complement”
MOHW officer Shin Bongchun “System maintain not confirm, Considering about study results and industry consult...
Pfizer, Open the 7th Pfizer R&D University
From 23rd of this month in Busan, Daegu, and Seoul
(Digital Bosa)
Pfizer Korea(President, Lee Dongsoo) hold ‘The 7th Pfizer R&D University’ with Dream CIS on 23rd in Busan, 29th in Daegu and 30th in Seoul.
Pfiz...
Local first hypertension +hyperlipidemia combination ‘Robelito’ available in the market soon
Hanmi – Sanofi Joint development – appointed reexamination in 6 years by MFDA
(Newspaper Chungnyun Doctor)
The fixed dose combination (FDC) of hypertension drug Irbesratan and hyperlipidemia drug Atorvastatin is...
Wholesales industry, Rising discontent to local pharmaceuticals which not accepting financial cost
Local companies N, H, and etc. distribution margin about 5% lower than Multinational companies.
Local pharmaceuticals’ low margin sales policies are worsening the deterioration of the business of wholesalers as m...
Wholesales businesses pointing 5 multinational pharmaceuticals as foes?
Bayer, Sanofi, GSK, Pfizer, Novartis --- Boycott resolution, including with discontinuation of product delivery
(The Yakup Shinmoon)
Pharmaceutical wholesale industry pointed to 5 multinational pharmaceutical comp...
Catch up Celebrex, Be #1 in anti inflamentary market
Competition in the NSAIDs market intensifies
(The Yakup Shinmoon)
Hanmi has launched Naxozol (complex NSAIDs PPI), market where Celebrex dominated, and officially began sales marketing which is starting to intensi...
‘The second Amosartan Naxozol, lead Hanmi growth for three years’
Naxozol Product Manager Dae-Sung Kyung
(Digital BOSA)
‘Patient charge will reduce by 33% and surpass Celebrex reputation’
“Naxozol is a product that will drive the growth of Hanmi for the next three years. You ...
Pharmaceuticals' wholesale margin cut “Boomerang effects”
When wholesaler stops medicine distribution, more distribution cost unavoidable
(The Yakup shinmoon)
Pharmaceuticals are reducing wholesale margin for profit reservation due to large-scale lump-sum drug price re...
